持股 5%以上股东深圳前海晟泰投资企业（有限合伙）保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：301201 证券简称：诚达药业 公告编号：2025-057 诚达药业股份有限公司 关于持股 5%以上股东减持计划时间届满的公告 公司于近日收到前海晟泰出具的《关于股份减持计划实施进展告知函》， 获悉截止 2025 年 12 月 28 日，前海晟泰减持计划实施期限已届满，期间累计减 持公司股份 2,906,400 股，占公司剔除回购专户股份数后总股本比例 1.92%。根 据《中华人民共和国证券法》《深圳证券交易所上市公司自律监管指引第 18 号 ——股东及董事、高级管理人员减持股份》等相关规定，现将相关情况公告如下： 一、股东减持情况 | 股东名称 | 减持方式 | 减持期间 | | 减持均价 （元/股） | 减持股数（股） | 减持股数占 剔除回购专 户股份数后 | 减持股数 占总股本 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 总股本比例 | 比例（%） | | | | | | ...

Group 1 - The core viewpoint of the news is that Chengda Pharmaceutical's stock performance and financial metrics indicate a mixed outlook, with significant financing activity and a notable decline in net profit despite revenue growth [1][2]. Group 2 - On December 24, Chengda Pharmaceutical's stock fell by 0.86%, with a trading volume of 151 million yuan. The financing buy-in amount for the day was 18.04 million yuan, while the financing repayment was 12.14 million yuan, resulting in a net financing buy of 5.90 million yuan. The total financing and securities balance reached 263 million yuan [1]. - The financing balance of Chengda Pharmaceutical is 263 million yuan, accounting for 4.11% of its market capitalization, which is above the 90th percentile of the past year, indicating a high level of financing activity [1]. - As of December 24, there were no shares repaid or sold in the securities lending market, with a securities lending balance of 0 yuan, which is also at a high level compared to the past year [1]. Group 3 - As of September 30, the number of shareholders for Chengda Pharmaceutical was 12,700, a decrease of 8.58% from the previous period. The average circulating shares per person increased by 36.16% to 8,577 shares [2]. - For the period from January to September 2025, Chengda Pharmaceutical achieved operating revenue of 285 million yuan, representing a year-on-year growth of 16.95%. However, the net profit attributable to the parent company was 16.77 million yuan, a decrease of 58.47% year-on-year [2]. Group 4 - Chengda Pharmaceutical has distributed a total of 133 million yuan in dividends since its A-share listing, with cumulative distributions of 89.62 million yuan over the past three years [3].

证券日报网12月24日讯 ，诚达药业在12月24日回答调研者提问时表示，公司募投项目产能逐渐释放， 能满足客户不同产品、不同阶段、不同规模订单的需求。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网12月24日讯 ，诚达药业在12月24日回答调研者提问时表示，公司目前已交付了客户部分小 核酸业务订单，后续将积极配合客户需求做好服务。具体信息请关注公司后续的定期报告。 ...

证券日报网12月24日讯 ，诚达药业在12月24日回答调研者提问时表示，公司具备稳定有效的质量体 系、生产特定产品所需要的设备和技术、供应链的顺畅和反应速度以及EHS和合规性等优势。同时公司 相关产品通过了中国NMPA、美国FDA、日本PMDA、韩国MFDS、意大利AIFA、英国MHRA、加拿大 HC、希腊等国家药政管理部门的审评，并取得了欧洲CEP认证证书，覆盖了全球主流市场的质量体系 认证，产品质量得到了客户的广泛认可。 （编辑 姚尧） ...

证券日报网12月24日讯 ，诚达药业在12月24日回答调研者提问时表示，公司细胞治疗"心梗项目""脑梗 项目"已完成GMP厂房及设施设备的设计、安装、调试、确认；完成脐带间充质干细胞的原代分离、培 养及冻存的技术转移，建立了种子库、主细胞库及工作细胞库；完成分析方法的开发和验证；启动工艺 验证，为IND申报做准备。 （编辑 姚尧） ...

Group 1 - The core business of the company currently focuses on small nucleic acids, specifically phosphoramidite monomers and GalNAc delivery systems [1] - The pricing for different monomers and delivery systems varies, with delivery systems being priced higher than monomers [1]

Core Viewpoint - Chengda Pharmaceutical focuses on providing key pharmaceutical intermediates and CDMO services for multinational pharmaceutical companies and research institutions, while also developing and selling L-carnitine series products and stem cell drugs [1] Group 1 - The company's main business includes the R&D, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and stem cell drugs [1] - Chengda Pharmaceutical is committed to continuous innovation in new products and processes, aiming to expand both the depth and breadth of its product offerings [1] - The company seeks to enrich its customer base through ongoing technological advancements and product development [1]

Group 1: Small Nucleic Acid Business - The company’s small nucleic acid business primarily involves phosphoramidite monomers and GalNAc delivery systems, with delivery systems priced higher than monomers [2] - The company has delivered part of its small nucleic acid business orders and will continue to meet customer needs, with further details available in future reports [2] - The company possesses a stable and effective quality system, necessary production equipment and technology, smooth supply chain responsiveness, and compliance advantages to become a supplier for multinational corporations (MNCs) [2][3] Group 2: Production Capacity and Main Business - The company’s fundraising projects are gradually releasing production capacity to meet diverse customer orders [3] - The main business includes providing key pharmaceutical intermediates, active pharmaceutical ingredients (APIs), CDMO services, L-carnitine series products, and stem cell drug development [3] - The company is focused on continuous innovation in new products and processes to expand product depth and breadth, aiming for a richer customer structure [3] Group 3: Stem Cell Project Progress - The company has completed the design, installation, debugging, and confirmation of GMP facilities for its cell therapy projects, including myocardial infarction and cerebral infarction [3] - Technical transfers for the isolation, culture, and cryopreservation of umbilical cord mesenchymal stem cells have been completed, establishing seed, master, and working cell banks [3] - The company has developed and validated analytical methods and initiated process validation in preparation for IND application [3] Group 4: Disclosure of Major Information - The activity did not involve the disclosure of any undisclosed major information [3]

证券日报网讯12月18日晚间，诚达药业（301201）发布公告称，公司将于2026年1月6日召开2026年第一 次临时股东会。 ...